It has been demonstrated that a TRPV1 receptor antagonist, capsazepine decreases the expression level of neurokinin-1 receptor, the receptor of SP, the pancreatic enzymes associated with pancreatitis, and the severity of histological changes in caerulein-induced experimental pancreatitis in mice. This evidence concerns the gene TFF2 and pancreatitis.